Targeted inhibition of the PI3K/AKT signaling pathway may enhance tumor control in NSCLC, antagonize the radiation-induced cellular defense mechanisms, and increase radiosensitivity in tumors [40]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.